Complement inhibition in C3 glomerulopathy
Highlights • Dysregulation of the alternative pathway of complement plays a critical role in C3 glomerulopathy. • Ultra-rare variants in complement genes are identified in about 40% of C3 glomerulopathy patients. • C3 nephritic factors are present in the majority of patients with C3 glomerulopathy....
Gespeichert in:
| Veröffentlicht in: | Seminars in immunology 2016-06, Vol.28 (3), p.241-249 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 3 |
| container_start_page | 241 |
| container_title | Seminars in immunology |
| container_volume | 28 |
| creator | Nester, Carla M Smith, Richard J.H |
| description | Highlights • Dysregulation of the alternative pathway of complement plays a critical role in C3 glomerulopathy. • Ultra-rare variants in complement genes are identified in about 40% of C3 glomerulopathy patients. • C3 nephritic factors are present in the majority of patients with C3 glomerulopathy. • Complement biomarker abnormalities are common in C3 glomerulopathy. • Complement inhibitors provide a targeted approach to the treatment of C3 glomerulopathy. |
| doi_str_mv | 10.1016/j.smim.2016.06.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811842177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044532316300495</els_id><sourcerecordid>1811842177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-dedb5bad1246744b7335dfbb3e2c401131fa42639a4e09d548464e97b1583a5f3</originalsourceid><addsrcrecordid>eNp9kUtLLDEQhYNc8f0HXMgsL0KPVUn6BZcLMviCARfqOqTT1ZqxuzMm3cL8e9OMunAhFNRZnHOgvmLsFGGOgNnFah4628151HOIA3yHHSCUWSIyLP5MWsokFVzss8MQVgAgZIF7bJ_nEjik2QE7X7hu3VJH_TCz_Yut7GBdH-VsIWbPrevIj61b6-Flc8x2G90GOvncR-zp-upxcZss72_uFpfLxEjEIamprtJK18hllktZ5UKkdVNVgriRgCiw0ZJnotSSoKxTWchMUplXmBZCp404Yn-3vWvv3kYKg-psMNS2uic3BoUFYiE55nm08q3VeBeCp0atve203ygENTFSKzUxUhMjBXGAx9DZZ_9YdVR_R76gRMO_rYHile-WvArGUm-otp7MoGpnf-___yNuWttbo9tX2lBYudH3kZ9CFbgC9TB9aXoSZgJAlqn4AFQWivw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811842177</pqid></control><display><type>article</type><title>Complement inhibition in C3 glomerulopathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nester, Carla M ; Smith, Richard J.H</creator><creatorcontrib>Nester, Carla M ; Smith, Richard J.H</creatorcontrib><description>Highlights • Dysregulation of the alternative pathway of complement plays a critical role in C3 glomerulopathy. • Ultra-rare variants in complement genes are identified in about 40% of C3 glomerulopathy patients. • C3 nephritic factors are present in the majority of patients with C3 glomerulopathy. • Complement biomarker abnormalities are common in C3 glomerulopathy. • Complement inhibitors provide a targeted approach to the treatment of C3 glomerulopathy.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2016.06.002</identifier><identifier>PMID: 27402056</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Biomarkers - metabolism ; C3 glomerulonephritis ; C3 glomerulopathy ; Complement ; Complement C3 - genetics ; Complement C3 - immunology ; Complement Inactivating Agents - therapeutic use ; Complement Pathway, Alternative ; Dense deposit disease ; Eculizumab ; Gene Frequency ; Genotype ; Glomerulonephritis, Membranous - genetics ; Glomerulonephritis, Membranous - immunology ; Glomerulonephritis, Membranous - therapy ; Humans ; Immunotherapy - methods ; Kidney - metabolism ; Kidney - pathology ; Membranoproliferative glomerulonephritis ; Polymorphism, Genetic</subject><ispartof>Seminars in immunology, 2016-06, Vol.28 (3), p.241-249</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-dedb5bad1246744b7335dfbb3e2c401131fa42639a4e09d548464e97b1583a5f3</citedby><cites>FETCH-LOGICAL-c411t-dedb5bad1246744b7335dfbb3e2c401131fa42639a4e09d548464e97b1583a5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1044532316300495$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27402056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nester, Carla M</creatorcontrib><creatorcontrib>Smith, Richard J.H</creatorcontrib><title>Complement inhibition in C3 glomerulopathy</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>Highlights • Dysregulation of the alternative pathway of complement plays a critical role in C3 glomerulopathy. • Ultra-rare variants in complement genes are identified in about 40% of C3 glomerulopathy patients. • C3 nephritic factors are present in the majority of patients with C3 glomerulopathy. • Complement biomarker abnormalities are common in C3 glomerulopathy. • Complement inhibitors provide a targeted approach to the treatment of C3 glomerulopathy.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Biomarkers - metabolism</subject><subject>C3 glomerulonephritis</subject><subject>C3 glomerulopathy</subject><subject>Complement</subject><subject>Complement C3 - genetics</subject><subject>Complement C3 - immunology</subject><subject>Complement Inactivating Agents - therapeutic use</subject><subject>Complement Pathway, Alternative</subject><subject>Dense deposit disease</subject><subject>Eculizumab</subject><subject>Gene Frequency</subject><subject>Genotype</subject><subject>Glomerulonephritis, Membranous - genetics</subject><subject>Glomerulonephritis, Membranous - immunology</subject><subject>Glomerulonephritis, Membranous - therapy</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Membranoproliferative glomerulonephritis</subject><subject>Polymorphism, Genetic</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtLLDEQhYNc8f0HXMgsL0KPVUn6BZcLMviCARfqOqTT1ZqxuzMm3cL8e9OMunAhFNRZnHOgvmLsFGGOgNnFah4628151HOIA3yHHSCUWSIyLP5MWsokFVzss8MQVgAgZIF7bJ_nEjik2QE7X7hu3VJH_TCz_Yut7GBdH-VsIWbPrevIj61b6-Flc8x2G90GOvncR-zp-upxcZss72_uFpfLxEjEIamprtJK18hllktZ5UKkdVNVgriRgCiw0ZJnotSSoKxTWchMUplXmBZCp404Yn-3vWvv3kYKg-psMNS2uic3BoUFYiE55nm08q3VeBeCp0atve203ygENTFSKzUxUhMjBXGAx9DZZ_9YdVR_R76gRMO_rYHile-WvArGUm-otp7MoGpnf-___yNuWttbo9tX2lBYudH3kZ9CFbgC9TB9aXoSZgJAlqn4AFQWivw</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Nester, Carla M</creator><creator>Smith, Richard J.H</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160601</creationdate><title>Complement inhibition in C3 glomerulopathy</title><author>Nester, Carla M ; Smith, Richard J.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-dedb5bad1246744b7335dfbb3e2c401131fa42639a4e09d548464e97b1583a5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Biomarkers - metabolism</topic><topic>C3 glomerulonephritis</topic><topic>C3 glomerulopathy</topic><topic>Complement</topic><topic>Complement C3 - genetics</topic><topic>Complement C3 - immunology</topic><topic>Complement Inactivating Agents - therapeutic use</topic><topic>Complement Pathway, Alternative</topic><topic>Dense deposit disease</topic><topic>Eculizumab</topic><topic>Gene Frequency</topic><topic>Genotype</topic><topic>Glomerulonephritis, Membranous - genetics</topic><topic>Glomerulonephritis, Membranous - immunology</topic><topic>Glomerulonephritis, Membranous - therapy</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Membranoproliferative glomerulonephritis</topic><topic>Polymorphism, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nester, Carla M</creatorcontrib><creatorcontrib>Smith, Richard J.H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nester, Carla M</au><au>Smith, Richard J.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complement inhibition in C3 glomerulopathy</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>28</volume><issue>3</issue><spage>241</spage><epage>249</epage><pages>241-249</pages><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>Highlights • Dysregulation of the alternative pathway of complement plays a critical role in C3 glomerulopathy. • Ultra-rare variants in complement genes are identified in about 40% of C3 glomerulopathy patients. • C3 nephritic factors are present in the majority of patients with C3 glomerulopathy. • Complement biomarker abnormalities are common in C3 glomerulopathy. • Complement inhibitors provide a targeted approach to the treatment of C3 glomerulopathy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27402056</pmid><doi>10.1016/j.smim.2016.06.002</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-5323 |
| ispartof | Seminars in immunology, 2016-06, Vol.28 (3), p.241-249 |
| issn | 1044-5323 1096-3618 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811842177 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergy and Immunology Animals Biomarkers - metabolism C3 glomerulonephritis C3 glomerulopathy Complement Complement C3 - genetics Complement C3 - immunology Complement Inactivating Agents - therapeutic use Complement Pathway, Alternative Dense deposit disease Eculizumab Gene Frequency Genotype Glomerulonephritis, Membranous - genetics Glomerulonephritis, Membranous - immunology Glomerulonephritis, Membranous - therapy Humans Immunotherapy - methods Kidney - metabolism Kidney - pathology Membranoproliferative glomerulonephritis Polymorphism, Genetic |
| title | Complement inhibition in C3 glomerulopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A34%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complement%20inhibition%20in%20C3%20glomerulopathy&rft.jtitle=Seminars%20in%20immunology&rft.au=Nester,%20Carla%20M&rft.date=2016-06-01&rft.volume=28&rft.issue=3&rft.spage=241&rft.epage=249&rft.pages=241-249&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2016.06.002&rft_dat=%3Cproquest_cross%3E1811842177%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811842177&rft_id=info:pmid/27402056&rft_els_id=S1044532316300495&rfr_iscdi=true |